Dacarbazine

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Image:Dacarbazine structure.png
Dacarbazine
Systematic (IUPAC) name
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
Identifiers
CAS number	4342-03-4
ATC code	L01AX04
PubChem	2942
DrugBank	APRD00331
Chemical data
Formula	C6H10N6O
Mol. mass	182.18
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	5 hours
Excretion	40% renal (unchanged)
Therapeutic considerations
Pregnancy cat.	C
Legal status	℞ Prescription only
Routes	IV

WikiDoc Resources for Dacarbazine
Articles
Most recent articles on Dacarbazine Most cited articles on Dacarbazine Review articles on Dacarbazine Articles on Dacarbazine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dacarbazine Images of Dacarbazine Photos of Dacarbazine Podcasts & MP3s on Dacarbazine Videos on Dacarbazine
Evidence Based Medicine
Cochrane Collaboration on Dacarbazine Bandolier on Dacarbazine TRIP on Dacarbazine
Clinical Trials
Ongoing Trials on Dacarbazine at Clinical Trials.gov Trial results on Dacarbazine Clinical Trials on Dacarbazine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dacarbazine NICE Guidance on Dacarbazine NHS PRODIGY Guidance FDA on Dacarbazine CDC on Dacarbazine
Books
Books on Dacarbazine
News
Dacarbazine in the news Be alerted to news on Dacarbazine News trends on Dacarbazine
Commentary
Blogs on Dacarbazine
Definitions
Definitions of Dacarbazine
Patient Resources / Community
Patient resources on Dacarbazine Discussion groups on Dacarbazine Patient Handouts on Dacarbazine Directions to Hospitals Treating Dacarbazine Risk calculators and risk factors for Dacarbazine
Healthcare Provider Resources
Symptoms of Dacarbazine Causes & Risk Factors for Dacarbazine Diagnostic studies for Dacarbazine Treatment of Dacarbazine
Continuing Medical Education (CME)
CME Programs on Dacarbazine
International
Dacarbazine en Espanol Dacarbazine en Francais
Businness
Dacarbazine in the Marketplace Patents on Dacarbazine
Experimental / Informatics
List of terms related to Dacarbazine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Dacarbazine (da-KAR-ba-zeen) (brand names DTIC, DTIC-Dome; also known as DIC or Imidazole Carboxamide) is an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma and Hodgkin lymphoma. Antineoplastic drugs are drugs which interfere with cell growth and impede the formation of new tissue - in this case, tumor tissue. These drugs are also known as cytotoxic drugs. Dacarbazine belongs to the family of chemicals known as alkylating agents. Dacarbazine is normally administered by injection (a shot) or intravenous infusion (IV) under the immediate supervision of a doctor or nurse.

History

See also: History of cancer chemotherapy

Dacarbazine gained FDA approval in May 1975 as DTIC-Dome. The drug was initially marketed by Bayer.

Side effects

Like many chemotherapy drugs, dacarbazine may have numerous serious side effects, because it interferes with normal cell growth as well as cancer cell growth. Among the most serious possible side effects are birth defects to children conceived or carried during treatment; sterility, possibly permanent; or immune suppression (reduced ability to fight infection or disease). Like most powerful drugs, it may produce more common side effects like nausea, fatigue, headache, etc.

Common uses

As of mid-2006, dacarbazine is commonly used as a single agent in the treatment of metastatic melanoma, and as part of the ABVD chemotherapy regimen to treat Hodgkin lymphoma.

Experimental

Dacarbazine + Oblimersen. In clinical trials for malignant melanoma.

Suppliers

Bayer continues to supply DTIC-Dome. There are also generic versions of dacarbazine available from APP, Bedford, Mayne Pharma and Sicor (Teva).

See also

• Melanoma
• Hodgkin disease
• ABVD
• History of cancer chemotherapy
• Alkylating antineoplastic agent

Sources

• MedLine, U.S. National Institutes of Health, National Library of Medicine, http://www.nlm.nih.gov/medline/
• Cancerweb, http://cancerweb.ncl.ac.uk/cancerweb/
• OncoLink, http://oncolink.upenn.edu/

v • d • e Chemotherapeutic agents/Antineoplastic agents (L01)
Alkylating and alkylating-like agents	Nitrogen mustards: (Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Bendamustine, Uramustine) Nitrosoureas:(Carmustine, Fotemustine, Lomustine, Streptozocin) Platinum (alkylating-like): (Carboplatin, Cisplatin, Oxaliplatin, Triplatin tetranitrate, Satraplatin) Alkyl sulfonates:(Busulfan, Treosulfan) Hydrazines:(Procarbazine, Dacarbazine, Temozolomide) Aziridines:(ThioTEPA)
Antimetabolites	Folic acid: (Aminopterin, Methotrexate, Pemetrexed, Raltitrexed). Purine:(Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Pentostatin, Thioguanine) Pyrimidine:(Capecitabine, Cytarabine, Decitabine, Fluorouracil, Floxuridine, Gemcitabine)
Spindle poison/mitotic inhibitor	Taxane: (Docetaxel, Larotaxel, Paclitaxel). Vinca: (Vinblastine, Vincristine, Vindesine, Vinorelbine).
Cytotoxic/antitumor antibiotics	Anthracycline family: (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Pixantrone, Valrubicin) streptomyces (Actinomycin, Bleomycin, Mitomycin, Plicamycin) - Hydroxyurea
Topoisomerase inhibitors	Camptotheca: (Camptothecin, Topotecan, Irinotecan, Rubitecan), Podophyllum:(Etoposide, Teniposide)
CI monoclonal antibodies	Receptor tyrosine kinase (Cetuximab, Panitumumab, Trastuzumab) - CD20 (Rituximab, Tositumomab) - other (Alemtuzumab, Bevacizumab, Gemtuzumab)
Photosensitizers	Aminolevulinic acid, Methyl aminolevulinate, Porfimer sodium, Verteporfin
Tyrosine kinase inhibitors	Axitinib, Bosutinib, Cediranib, Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, Vandetanib
Cyclin-dependent kinase inhibitor	Seliciclib
Other	retinoids (Alitretinoin, Tretinoin), Fusion protein (Aflibercept) - Altretamine, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase (Pegaspargase), Bexarotene, Bortezomib, Celecoxib, Denileukin diftitox, Elesclomol, Estramustine, Irofulven, Ixabepilone, Masoprocol, Mitotane, Oblimersen, Testolactone, Tipifarnib, Trabectedin

v • d • e WikiDoc Research Resources for Dacarbazine (Click show to right to view)
Articles on Dacarbazine	Most recent articles on Dacarbazine • Most cited articles on Dacarbazine • Review articles on Dacarbazine • Articles on Dacarbazine in N Eng J Med, Lancet, BMJ
Media (Slides, Video, Images, MP3) on Dacarbazine	Powerpoint slides on Dacarbazine • Images of Dacarbazine • Photos of Dacarbazine • Podcasts & MP3s on Dacarbazine • Videos on Dacarbazine
Evidence Based Medicine Regarding Dacarbazine	Cochrane Collaboration on Dacarbazine • Bandolier on Dacarbazine • TRIP on Dacarbazine
Cost Effectiveness of Dacarbazine	Cost Effectiveness of Dacarbazine
Clinical Trials Involving Dacarbazine	Ongoing Trials on Dacarbazine at Clinical Trials.gov • Trial results on Dacarbazine • Clinical Trials on Dacarbazine at Google
Guidelines / Policies / Government Resources (FDA/CDC) Regarding Dacarbazine	US National Guidelines Clearinghouse on Dacarbazine • NICE Guidance on Dacarbazine • NHS PRODIGY Guidance • FDA on Dacarbazine • CDC on Dacarbazine
Textbook Information on Dacarbazine	Books and Textbook Information on Dacarbazine
Pharmacology Resources on Dacarbazine	Dosing of Dacarbazine • Drug interactions with Dacarbazine • Side effects of Dacarbazine • Allergic reactions to Dacarbazine • Overdose information on Dacarbazine • Carcinogenicity information on Dacarbazine • Dacarbazine in pregnancy • Pharmacokinetics of Dacarbazine •
Genetics, Pharmacogenomics, and Proteinomics of Dacarbazine	Genetics of Dacarbazine • Pharmacogenomics of Dacarbazine • Proteomics of Dacarbazine
Newstories on Dacarbazine	Dacarbazine in the news • Be alerted to news on Dacarbazine • News trends on Dacarbazine
Commentary on Dacarbazine	Blogs on Dacarbazine
Patient Resources on Dacarbazine	Patient resources on Dacarbazine • Discussion groups on Dacarbazine • Patient Handouts on Dacarbazine • Directions to Hospitals Treating Dacarbazine • Risk calculators and risk factors for Dacarbazine
Healthcare Provider Resources on Dacarbazine	Symptoms of Dacarbazine • Causes & Risk Factors for Dacarbazine • Diagnostic studies for Dacarbazine • Treatment of Dacarbazine
Continuing Medical Education (CME) Programs on Dacarbazine	CME Programs on Dacarbazine
International Resources on Dacarbazine	Dacarbazine en Espanol • Dacarbazine en Francais
Business Resources on Dacarbazine	Dacarbazine in the Marketplace • Patents on Dacarbazine
Informatics Resources on Dacarbazine	List of terms related to Dacarbazine

WikiDoc Help Menu Quick Start.. Get Started Here! How to Login How to Search Pages How to Start a New Page How to Edit a Page Cheat Sheet Editing basics Learning Basic Formatting How to make Links in WikiDoc & to External Sites How to Make Lists How to Ignoring Formatting Adding References or Footnotes to Articles Tracking Changes You Have Made How to Put an Article Into a Category When Multiple Topics Should Go To The Same Page (MI, Acute MI, AMI) Using Redirection Advanced editing How to Make Tables How to Insert Images and Other Media How to Add Video Help:How to Make Columns Web Colors How To Make Templates How to Move Pages Inserting Dynamic Dates and Times Inserting WikiDoc Statistics Editing the Table of Contents Communicating your edits Let others know what you changed: The importance of Edit Summaries Minor Edits Edit Conflicts Help Videos You Can Watch Getting Started Video

Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .